Möchten Sie immer auf dem neuesten Stand bleiben?

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their...

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing;...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Business executive Sabrina Kuykendall officially announces the launch of the Sabrina Kuykendall University Bound Grant, an academic initiative designed to...

ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and...

Bankable Feasibility Study (BFS) engineering integration advances: Fluor Corporation (“Fluor”), as lead engineering firm, continues to integrate major work packages and coordinate technical...

LincNutri launches 10-in-1 DHT Blocker for Women. This premium softgel with saw palmetto & biotin supports a healthy hair environment.

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer ...

Wuxi, China, June 23, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that the Company has established a...

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to...